Cargando…

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications

BACKGROUND: No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Diederick, Thangavelu, Amudha, Broadhead, Timothy, Chen, Inga, Burke, Dermot, Hutson, Richard, Johnson, Racheal, Kaufmann, Angelika, Lodge, Peter, Nugent, David, Quyn, Aaron, Theophilou, Georgios, Laios, Alexandros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638711/
https://www.ncbi.nlm.nih.gov/pubmed/37951927
http://dx.doi.org/10.1186/s13048-023-01303-1
_version_ 1785133653475459072
author de Jong, Diederick
Thangavelu, Amudha
Broadhead, Timothy
Chen, Inga
Burke, Dermot
Hutson, Richard
Johnson, Racheal
Kaufmann, Angelika
Lodge, Peter
Nugent, David
Quyn, Aaron
Theophilou, Georgios
Laios, Alexandros
author_facet de Jong, Diederick
Thangavelu, Amudha
Broadhead, Timothy
Chen, Inga
Burke, Dermot
Hutson, Richard
Johnson, Racheal
Kaufmann, Angelika
Lodge, Peter
Nugent, David
Quyn, Aaron
Theophilou, Georgios
Laios, Alexandros
author_sort de Jong, Diederick
collection PubMed
description BACKGROUND: No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women. Prerequisites to facilitate this surgical paradigm shift and subsequent ramifications need to be addressed. This quality improvement study assessed 559 women with advanced EOC who had cytoreductive surgery between January 2014 and December 2019 in our tertiary referral centre. Following implementation of the Enhanced Recovery After Surgery (ERAS) pathway and prehabilitation protocols, the surgical management paradigm in advanced EOC patients shifted towards maximal surgical effort cytoreduction in 2016. Surgical outcome parameters before, during, and after this paradigm shift were compared. The primary outcome measure was residual disease (RD). The secondary outcome parameters were postoperative morbidity, operative time (OT), length of stay (LOS) and progression-free-survival (PFS). RESULTS: R0 resection rate in patients with advanced EOC increased from 57.3% to 74.4% after the paradigm shift in surgical management whilst peri-operative morbidity and delays in adjuvant chemotherapy were unchanged. The mean OT increased from 133 + 55 min to 197 + 85 min, and postoperative high dependency/intensive care unit (HDU/ICU) admissions increased from 8.1% to 33.1%. The subsequent mean LOS increased from 7.0 + 2.6 to 8.4 + 4.9 days. The median PFS was 33 months. There was no difference for PFS in the three time frames but a trend towards improvement was observed. CONCLUSIONS: Improved CC 0 surgical cytoreduction rates without compromising morbidity in advanced EOC is achievable owing to the right conditions. Maximal effort cytoreductive surgery should solely be carried out in high output tertiary referral centres due to the associated substantial prerequisites and ramifications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01303-1.
format Online
Article
Text
id pubmed-10638711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106387112023-11-11 Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications de Jong, Diederick Thangavelu, Amudha Broadhead, Timothy Chen, Inga Burke, Dermot Hutson, Richard Johnson, Racheal Kaufmann, Angelika Lodge, Peter Nugent, David Quyn, Aaron Theophilou, Georgios Laios, Alexandros J Ovarian Res Research BACKGROUND: No residual disease (CC 0) following cytoreductive surgery is pivotal for the prognosis of women with advanced stage epithelial ovarian cancer (EOC). Improving CC 0 resection rates without increasing morbidity and no delay in subsequent chemotherapy favors a better outcome in these women. Prerequisites to facilitate this surgical paradigm shift and subsequent ramifications need to be addressed. This quality improvement study assessed 559 women with advanced EOC who had cytoreductive surgery between January 2014 and December 2019 in our tertiary referral centre. Following implementation of the Enhanced Recovery After Surgery (ERAS) pathway and prehabilitation protocols, the surgical management paradigm in advanced EOC patients shifted towards maximal surgical effort cytoreduction in 2016. Surgical outcome parameters before, during, and after this paradigm shift were compared. The primary outcome measure was residual disease (RD). The secondary outcome parameters were postoperative morbidity, operative time (OT), length of stay (LOS) and progression-free-survival (PFS). RESULTS: R0 resection rate in patients with advanced EOC increased from 57.3% to 74.4% after the paradigm shift in surgical management whilst peri-operative morbidity and delays in adjuvant chemotherapy were unchanged. The mean OT increased from 133 + 55 min to 197 + 85 min, and postoperative high dependency/intensive care unit (HDU/ICU) admissions increased from 8.1% to 33.1%. The subsequent mean LOS increased from 7.0 + 2.6 to 8.4 + 4.9 days. The median PFS was 33 months. There was no difference for PFS in the three time frames but a trend towards improvement was observed. CONCLUSIONS: Improved CC 0 surgical cytoreduction rates without compromising morbidity in advanced EOC is achievable owing to the right conditions. Maximal effort cytoreductive surgery should solely be carried out in high output tertiary referral centres due to the associated substantial prerequisites and ramifications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13048-023-01303-1. BioMed Central 2023-11-11 /pmc/articles/PMC10638711/ /pubmed/37951927 http://dx.doi.org/10.1186/s13048-023-01303-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
de Jong, Diederick
Thangavelu, Amudha
Broadhead, Timothy
Chen, Inga
Burke, Dermot
Hutson, Richard
Johnson, Racheal
Kaufmann, Angelika
Lodge, Peter
Nugent, David
Quyn, Aaron
Theophilou, Georgios
Laios, Alexandros
Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
title Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
title_full Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
title_fullStr Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
title_full_unstemmed Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
title_short Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
title_sort prerequisites to improve surgical cytoreduction in figo stage iii/iv epithelial ovarian cancer and subsequent clinical ramifications
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638711/
https://www.ncbi.nlm.nih.gov/pubmed/37951927
http://dx.doi.org/10.1186/s13048-023-01303-1
work_keys_str_mv AT dejongdiederick prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT thangaveluamudha prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT broadheadtimothy prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT cheninga prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT burkedermot prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT hutsonrichard prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT johnsonracheal prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT kaufmannangelika prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT lodgepeter prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT nugentdavid prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT quynaaron prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT theophilougeorgios prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications
AT laiosalexandros prerequisitestoimprovesurgicalcytoreductioninfigostageiiiivepithelialovariancancerandsubsequentclinicalramifications